Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.69 |
| ▸ | KDR | P35968 | 18/20 | 0.61 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
| ▸ | FLT4 | P35916 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12303668 | 1.00 | RET (0.69) | RETKDRCSF1RKITPDGFRA | |
| SCHEMBL2456697 | 1.00 | RET (0.69) | RETKDRCSF1RKITPDGFRA | |
| SCHEMBL2456695 | 1.00 | RET (0.69) | RETKDRCSF1RKITPDGFRA | |
| SCHEMBL2454668 | 0.83 | RET (0.74) | RETKDRCSF1RKITPDGFRA | |
| SCHEMBL2453267 | 0.83 | RET (0.74) | RETKDRCSF1RKITPDGFRA | |
| SCHEMBL2454283 | 0.82 | RET (0.73) | RETKDRCSF1RKITPDGFRA | |
| SCHEMBL2454285 | 0.82 | RET (0.73) | RETKDRCSF1RKITPDGFRA | |
| SCHEMBL12303635 | 0.82 | RET (0.73) | RETKDRCSF1RKITPDGFRA | |
| SCHEMBL12303540 | 0.82 | RET (1.00) | RETKDRCSF1RKITPDGFRA | |
| SCHEMBL2453281 | 0.82 | RET (1.00) | RETKDRCSF1RKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013153-B2 | Substituted pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-09-06 | — | — | US | claimed |
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | DTYMK, TK1, DCK | RET 577/4885KDR 1975/4885CSF1R 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.